spacer
home > ebr > spring 2018 > proactive progress
PUBLICATIONS
European Biopharmaceutical Review

Proactive Progress

Although gene therapy is a promising tool within disease treatment, progress has been slow in developing effective clinical approaches. The issue lies in the difficulty to develop safe and efficient gene-delivery systems (1). An ideal vector system should deliver a certain amount of genetic material into the target cells. The transfer should be stable and cell-type-specific, allowing a high and controllable expression of the gene product without causing an immune response or other toxicity (2).

The revolutionary potential of adeno-associated viruses (AAV) is undisputed and underlined by the growing number of clinical trials using them as a central gene delivery tool. Recent groundbreaking success stories from clinical AAV applications have been reported in the media. The publication of one therapy successfully treating haemophilia B via liver-specific AAV vectors demonstrated their long-term potency, aside from a low number of temporary side effects (3). The first AAV FDA approval for an AAV-based therapy in history happened just before Christmas 2017, giving patients who suffer from bi-allelic RPE65 mutationassociated retinal dystrophy new hope that they may retain their eyesight (4). Impressive in their own right, these publications also help to uncover the secret to success when it comes to engaging in the development of any new AAV-based therapy: viral engineering – customising existing virus models to fit the specific goals of the therapeutic approach. More precisely, both the genetic strategy itself – in terms of plasmid manufacturing – and the viral capsid carrying it to the designated cell type or tissue need to be optimised to fit every aspect of their intended application, including the determination of the correct titre of the gene shuttle (see Figure 1).

A Solid Start

Among other applications, plasmid DNA is often used as starting material in the Good Manufacturing Practicecompliant (GMP) production of recombinant viruses, antibodies, and RNA, where these are the API used in clinical trials. In many cases, producing the plasmid DNA under GMP conditions is not necessary. An alternative is the highquality grade plasmid DNA, which is both highly purified and well-characterised, thus meeting the requirements of most regulating agencies (5). High-quality grade plasmid DNA is produced based on a research cell bank and the patented ccc-grade DNA technology. A number of quality controls, both to the cell bank and to the plasmid DNA product, ensure that the final result is a product designed especially for the intended application that complies with the appropriate regulatory standards (5).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Tatjana Buchholz holds degrees in molecular biotechnology (BSc) and genome-based systems biology (MSc) from the Bielefeld University, Germany, and is an examined medical technical assistant. Her bachelor’s thesis was occupied with signal studies of the promoter activity of the nuclear LHCII translational repressor NAB1 in the microalgae Chlamydomonas reinhardtii. Tatjana's master’s thesis was concerned with MC technology optimisation. She joined PlasmidFactory in Bielefeld, Germany, as Marketing Manager in 2016. 

Dr Carl J Christel has a strong background in molecular physiology that has helped him advise, organise, and accompany gene engineering projects for commercial and academic clients. In 2009, he gained his PhD from the Department for Pharmacology and Toxicology at the Technical University, Munich, and completed four years of post-doctorate work at the Department of Molecular Physiology and Biophysics at the University of Iowa, US. Since 2013, Carl works in the commercial biotech sector as Senior Manager for Sales and Marketing at Sirion Biotech in Munich, Germany.

Dr Hüseyin Besir studied chemistry at the Ludwig Maximilian University in Munich, Germany. His dissertation at the Max Planck Institute of Biochemistry in Martinsried focused on lipid induced crystallisation of halophilic archaeal rhodopsins. After his post-doctoral work at Roche Diagnostics in Penzberg, Hüseyin became sub-project leader of the EU-funded project Interaction Proteome at the Max Planck Institute in Munich and later Head of the Protein Expression and Purification Core Facility at EMBL in Heidelberg. In 2016, he joined PROGEN Biotechnik in Heidelberg as Head of R&D.
spacer
Tatjana Buchholz
spacer
spacer
spacer
Dr Carl J Christel
spacer
spacer
spacer
Dr Hüseyin Besir
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Enjoy form function and comfort with Teknomek’s new class 5 certified PU chair

Teknomek has released a strong, durable and soft PU (poly-urethane) chair designed for use in production, laboratory and healthcare environments. The product is clean room grade 5 certified and can accommodate weights of up to 150 kg.
More info >>

White Papers

The Impact of Components on Drug Quality and Risk Mitigation

West Pharmaceutical Services, Inc.

Expectations for quality by regulatory agencies are increasing at a very fast pace, especially for prefilled drug delivery formats, thanks to increased focus on reducing risk to patient safety. The trend has resulted in delays for new drug applications, more recalls of marketed products and even drug shortages if the container system and drug contents are suspect for quality issues. The pharmaceutical market is now requiring manufacturers of containers and components to meet new expectations with a quality culture and very high product reliability. The need to bridge the gap and provide superior quality products has been a driver for manufacturing technology investments, more robust control strategies and the introduction of next generation elastomer components.
More info >>

 
Industry Events

Partnerships in Clinical Trials Europe 2018

27-29 November 2018, CCIB, Barcelona

Partnerships in Clinical Trials Europe is back – and bigger than ever. Europe’s most complete clinical meeting is bringing together 1000+ of the industry’s leading experts this November for it’s 17th annual gathering, and you’re invited!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement